The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
Open accessAbstract
BACKGROUND: CD19-specific chimeric antigen receptor (CAR) T cells induce high rates of initial response among patients with relapsed B-cell acute lymphoblastic leukemia (ALL) and long-term remissions in a subgroup of patients. METHODS: We conducted a phase 1 trial involving adults with relapsed B-cell ALL who received an infusion of autologous T cells expressing the 19-28z CAR at the Memorial Sloan Kettering Cancer Center (MSKCC). Safety and long-term outcomes were assessed, as were their associations with demographic, clinical, and disease characteristics. RESULTS: A total of 53 adults received 19-28z CAR T cells that were manufactured at MSKCC. After infusion, severe cytokine release syndrome occurred in 14 of 53 patients (26%; 95% confidence interval [CI], 15 to 40); 1 patient died. Complete remission was observed in 83% of the patients. At a median follow-up of 29 months (range, 1 to 65), the median event-free survival was 6.1 months (95% CI, 5.0 to 11.5), and the median overall survival was 12.9 months (95% CI, 8.7 to 23.4). Patients with a low disease burden (<5% bone marrow blasts) before treatment had markedly enhanced remission duration and survival, with a median event-free survival of 10.6 months (95% CI, 5.9 to not reached) and a median overall survival of 20.1 months (95% CI, 8.7 to not reached). Patients with a higher burden of disease (≥5% bone marrow blasts or extramedullary disease) had a greater incidence of the cytokine release syndrome and neurotoxic events and shorter long-term survival than did patients with a low disease burden. CONCLUSIONS: In the entire cohort, the median overall survival was 12.9 months. Among patients with a low disease burden, the median overall survival was 20.1 months and was accompanied by a markedly lower incidence of the cytokine release syndrome and neurotoxic events after 19-28z CAR T-cell infusion than was observed among patients with a higher disease burden. (Funded by the Commonwealth Foundation for Cancer Research and others; ClinicalTrials.gov number, NCT01044069 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“It has been reported that CAR-T cell therapy shows high response rates to B-ALL patients in different age groups [117–119].”
From Immunosenescence: a key player in cancer development (2020) · cites this paper as [119]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413
Lee, D. W., Kochenderfer, J. N., Stetler-Stevenson, M., Cui, Y. K., Delbrook, C., Feldman, S. A., Fry, T. J., Orentas, R., Sabatino, M., Shah, N. N., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61403-3 · Cited by 2,898
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
Davila, M. L., Rivière, I., Wang, X., Bartido, S. M., Park, J. H., Curran, K. J., Chung, S. S., Stefanski, J., Bórquez-Ojeda, O., Olszewska, M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008226 · Cited by 2,514
Self-citationBlinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia
Kantarjian, H. M., Stein, A. S., Gökbuget, N., Fielding, A. K., Schuh, A. C., Ribera, J., Wei, A. H., Dombret, H., Foà, R., Bassan, R., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1609783 · Cited by 2,204
CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients
Turtle, C. J., Hanafi, L.-A., Berger, C., Gooley, T. A., Cherian, S., Hudecek, M., Sommermeyer, D., Melville, K., Pender, B., Budiarto, T. M., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci85309 · Cited by 2,112
Brentjens, R. J., Davila, M. L., Riviere, I., Park, J., Wang, X., Cowell, L. G., Bartido, S., Stefanski, J., Taylor, C., Olszewska, M., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005930 · Cited by 2,063
Self-citationT-cell invigoration to tumour burden ratio associated with anti-PD-1 response
Huang, A. C., Postow, M. A., Orlowski, R. J., Mick, R., Bengsch, B., Manne, S., Xu, W., Harmon, S., Giles, J. R., Wenz, B., et al. (2017) · Nature · doi:10.1038/nature22079 · Cited by 1,664
Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia
Kantarjian, H. M., DeAngelo, D. J., Stelljes, M., Martinelli, G., Liedtke, M., Stock, W., Gökbuget, N., O'Brien, S. M., Wang, K., Wang, T., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1509277 · Cited by 1,444
Brentjens, R. J., Rivière, I., Park, J. H., Davila, M. L., Wang, X., Stefanski, J., Taylor, C., Yeh, R., Bartido, S. M., Bórquez-Ojeda, O., et al. (2011) · Blood · doi:10.1182/blood-2011-04-348540 · Cited by 1,293
Self-citationTopp, M. S., Kufer, P., Gökbuget, N., Goebeler, M., Klinger, M., Neumann, S., Horst, H.-A., Raff, T., Viardot, A., Schmid, M., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.7270 · Cited by 914
Cited by
Sorted by citations
Items 501–600 of 1,004
Immunotherapy in non-small cell lung cancer: update and new insights
Mielgo-Rubio, X., Uribelarrea, E. A., Cortés, L. Q., & Moyano, M. S. (2021) · Journal of Clinical and Translational Research · doi:10.18053/jctres.07.202101.001 · Cited by 65
Short, N. J., Kantarjian, H. M., & Jabbour, E. J. (2021) · Leukemia · doi:10.1038/s41375-021-01277-3 · Cited by 66
Aldoss, I. T., Otoukesh, S., Zhang, J., Mokhtari, S., Ngo, D., Mojtahedzadeh, M., Malki, M. M. A., Salhotra, A., Ali, H., Aribi, A. M., et al. (2021) · Cancer · doi:10.1002/cncr.33967 · Cited by 65
Yan, X., Chen, D., Wang, Y., Guo, Y., Tong, C., Wei, J., Zhang, Y., Wu, Z., & Han, W. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00915-1 · Cited by 65
Self-citationAldoss, I. T., Khaled, S. K., Wang, X., Palmer, J. M., Wang, Y., Wagner, J. R., Clark, M. C., Simpson, J., Paul, J. A., Vyas, V., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-2038 · Cited by 65
Self-citationPérez, C. A., Carmona-Luque, M. D., Benabdellah, K., & Herrera, C. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1165870 · Cited by 69
Nguyen, T., & Barr, F. G. (2018) · Molecules · doi:10.3390/molecules23112798 · Cited by 69
Zhao, X., Liu, Y., Xu, L., Wang, Y., Zhang, X., Chen, H., Chen, Y., Han, W., Sun, Y., Yan, C., et al. (2019) · American Journal of Hematology · doi:10.1002/ajh.25417 · Cited by 65
Self-citationChimeric Antigen Receptor beyond CAR-T Cells
Qin, V. M., D’Souza, C., Neeson, P. J., & Zhu, J. J. (2021) · Cancers · doi:10.3390/cancers13030404 · Cited by 65
Mohty, M., Gauthier, J., Malard, F., Aljurf, M. D., Bazarbachi, A. A., Chabannon, C., Kharfan‐Dabaja, M. A., Savani, B. N., Huang, H., Kenderian, S. S., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0615-5 · Cited by 65
Goto, S., Sakoda, Y., Adachi, K., Sekido, Y., Yano, S., Eto, M., & Tamada, K. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-02853-3 · Cited by 64
Comparing CAR and TCR engineered T cell performance as a function of tumor cell exposure
Wachsmann, T. L. A., Wouters, A. K., Remst, D. F. G., Hagedoorn, R. S., Meeuwsen, M. H., van Diest, E., Leusen, J. H. W., Kuball, J. H. E., Falkenburg, J. H. F., & Heemskerk, M. H. M. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2033528 · Cited by 66
Engineering strategies to safely drive CAR T-cells into the future
Rossi, M., & Breman, E. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1411393 · Cited by 68
Novel strategies to manage CAR-T cell toxicity
Mulvey, A., Trueb, L., Coukos, G., & Arber, C. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-01100-5 · Cited by 69
Novel Approaches to Acute Myeloid Leukemia Immunotherapy
Beyar‐Katz, O., & Gill, S. I. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3016 · Cited by 65
Modeling anti-CD19 CAR T cell therapy in humanized mice with human immunity and autologous leukemia
Jin, C., Xia, J., Rafiq, S., Huang, X., Hu, Z., Zhou, X., Brentjens, R. J., & Yang, Y. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.12.013 · Cited by 65
Self-citationNon-viral transfection technologies for next-generation therapeutic T cell engineering
Raes, L., Smedt, S. C. D., Raemdonck, K., & Braeckmans, K. (2021) · Biotechnology Advances · doi:10.1016/j.biotechadv.2021.107760 · Cited by 67
CAR T-cell immunotherapy of B-cell malignancy: the story so far
Halim, L., & Maher, J. F. (2020) · Therapeutic Advances in Vaccines and Immunotherapy · doi:10.1177/2515135520927164 · Cited by 65
Alzubi, J., Dettmer‐Monaco, V., Kuehle, J., Thorausch, N., Seidl, M., Taromi, S., Schamel, W. W. A., Zeiser, R., Abken, H., Cathomen, T., et al. (2020) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2020.06.014 · Cited by 63
Frontiers in cancer immunotherapy—a symposium report
Cable, J., Greenbaum, B. D., Pe’er, D., Bollard, C. M., Bruni, S., Griffin, M. E., Allison, J. P., Wu, C. J., Subudhi, S. K., Mardis, E. R., et al. (2020) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14526 · Cited by 65
Self-citationRecent advances in breast cancer immunotherapy: The promising impact of nanomedicines
Hashemzadeh, N., Dolatkhah, M., Adibkia, K., Aghanejad, A., Barzegar-Jalali, M., Omidi, Y., & Barar, J. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119110 · Cited by 64
Li, L., Li, Q., Yan, Z., Sheng, L., Fu, D., Xu, P., Wang, L., & Zhao, W. (2022) · Scientific Reports · doi:10.1038/s41598-022-16616-2 · Cited by 67
Cortés-López, M., Schulz, L., Enculescu, M., Paret, C., Spiekermann, B., Quesnel-Vallières, M., Torres-Diz, M., Unic, S., Busch, A., Orekhova, A., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31818-y · Cited by 65
Bader, P., Rössig, C., Hutter, M., Ayuk, F. A., Baldus, C. D., Bücklein, V., Bonig, H. B., Cario, G., Einsele, H., Holtick, U., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2022008981 · Cited by 65
Li, N., Quan, A., Li, D., Pan, J., Ren, H., Hoeltzel, G. D., de Val, N., Ashworth, D., Ni, W., Zhou, J., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37616-4 · Cited by 65
Light-responsive nanomedicine for cancer immunotherapy
Kang, W., Liu, Y., & Wang, W. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.05.016 · Cited by 64
Yurkiewicz, I. R., Muffly, L. S., & Liedtke, M. (2018) · Drug Design Development and Therapy · doi:10.2147/dddt.s150317 · Cited by 63
Kimmel, G. J., Locke, F. L., & Altrock, P. M. (2021) · Proceedings of the Royal Society B Biological Sciences · doi:10.1098/rspb.2021.0229 · Cited by 68
Immunotherapy and targeted therapy—the new roadmap in cancer treatment
Shahid, K., Khalife, M., Dabney, R. S., & Phan, A. T. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2019.05.58 · Cited by 63
de Weerdt, I., Lameris, R., Ruben, J. M., de Boer, R., Kloosterman, J., King, L. A., Levin, M., Parren, P. W. H. I., de Gruijl, T. D., Kater, A. P., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4576 · Cited by 63
Bunse, M., Pfeilschifter, J. M., Bluhm, J., Zschummel, M., Joedicke, J. J., Wirges, A., Stark, H., Kretschmer, V., Chmielewski, M. M., Uckert, W., et al. (2021) · Nature Communications · doi:10.1038/s41467-020-20488-3 · Cited by 64
Orvain, C., Boulch, M., Bousso, P., Allanore, Y., & Avouac, J. (2021) · Arthritis & Rheumatology · doi:10.1002/art.41812 · Cited by 62
Yang, Y., McCloskey, J. E., Yang, H., Puc, J., Alcaina, Y., Vedvyas, Y., Gallegos, A. A. G., Ortíz-Sánchez, E., de Stanchina, E., Min, I. M., et al. (2021) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-21-0062 · Cited by 64
Adapter CAR T cells to counteract T-cell exhaustion and enable flexible targeting in AML
Nixdorf, D., Sponheimer, M., Berghammer, D., Engert, F., Bader, U., Philipp, N., Pasikhani, M. K., Straub, T., Rohrbacher, L., Wange, L. E., et al. (2023) · Leukemia · doi:10.1038/s41375-023-01905-0 · Cited by 63
Tumor-Derived Small Extracellular Vesicles Inhibit the Efficacy of CAR T Cells against Solid Tumors
Zhong, W., Xiao, Z., Qin, Z., Yang, J., Wen, Y., Yu, Z., Li, Y., Sheppard, N. C., Fuchs, S. Y., Xu, X., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-22-2220 · Cited by 63
Riding the storm: managing cytokine-related toxicities in CAR-T cell therapy
Hughes, A. D., Teachey, D. T., & Diorio, C. J. (2024) · Seminars in Immunopathology · doi:10.1007/s00281-024-01013-w · Cited by 69
Engineering Nano‐Therapeutics to Boost Adoptive Cell Therapy for Cancer Treatment
Zheng, C., Zhang, J., Chan, H. F., Hu, H., Lv, S., Na, N., Tao, Y., & Li, M. (2021) · Small Methods · doi:10.1002/smtd.202001191 · Cited by 61
No free rides: management of toxicities of novel immunotherapies in ALL, including financial
Jain, T., & Litzow, M. R. (2018) · Hematology · doi:10.1182/asheducation-2018.1.25 · Cited by 61
Xu, X., Huang, S., Xiao, X., Sun, Q., Liang, X., Chen, S., Zhao, Z., Huo, Z., Tu, S., & Li, Y. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.569117 · Cited by 62
Chen, C., Hao, X., Lai, X., Liu, L., Zhu, J., Shao, H., Huang, D., Gu, H., Zhang, T., Yu, Z., et al. (2021) · Science Advances · doi:10.1126/sciadv.abd6280 · Cited by 63
Faude, S., Wei, J. M., Muralidharan, K., Xu, X., Wertheim, G. B. W., Paessler, M. E., Bhoj, V. G., Grupp, S. A., Maude, S. L., Rheingold, S. R., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020004038 · Cited by 62
Organoid models of the tumor microenvironment and their applications
Xia, T., Du, W., Chen, X., & Zhang, Y.-N. (2021) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.16578 · Cited by 63
Bachiller, M., Pérez-Amill, L., Battram, A. M., Carné, S. C., Najjar, A. M., Verhoeyen, E., Juan, M., Urbano-Ispizúa, Á., & Martín-Antonio, B. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002866 · Cited by 61
CAR T Cell Therapy for Chronic Lymphocytic Leukemia: Successes and Shortcomings
Todorović, Ž., Todorovic, D., Marković, V., Ladjevac, N., Zdravković, N., Djurdjevic, P. M., Arsenijević, N., Milovanović, M., Arsenijević, A., & Milovanović, J. (2022) · Current Oncology · doi:10.3390/curroncol29050293 · Cited by 62
Lu, Y., Jia, L., Zheng, Z., Tran, E., Robbins, P. F., & Rosenberg, S. A. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0299 · Cited by 62
CEACAM7 Is an Effective Target for CAR T-cell Therapy of Pancreatic Ductal Adenocarcinoma
Raj, D., Nikolaidi, M., Garces, I., Lorizio, D., Castro, N. M., Caiafa, S. G., Moore, K. M., Brown, N. F., Kocher, H. M., Duan, X., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2163 · Cited by 62
Couturier, M., Thomas, X., Raffoux, E., Huguet, F., Berthon, C., Simand, C., Gallego-Hernanz, M.-P., Hicheri, Y., Hunault, M., Saillard, C., et al. (2020) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2020.1844198 · Cited by 60
Stein-Merlob, A. F., Rothberg, M. V., Holman, P., & Yang, E. H. (2021) · Current Cardiology Reports · doi:10.1007/s11886-021-01440-3 · Cited by 60
CAR-T Plus Radiotherapy: A Promising Combination for Immunosuppressive Tumors
Qin, V. M., Haynes, N. M., D’Souza, C., Neeson, P. J., & Zhu, J. J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.813832 · Cited by 61
Time to evolve: predicting engineered T cell-associated toxicity with next-generation models
Donnadieu, E., Luu, M., Alb, M., Anliker, B., Arcangeli, S., Bonini, C., Angelis, B. D., Choudhary, R., Espie, D., Galy, A. H. M., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003486 · Cited by 66
Wang, F., Wu, L., Yin, L., Shi, H. M., Gu, Y., & Xing, N. (2022) · Clinical and Translational Medicine · doi:10.1002/ctm2.901 · Cited by 60
Current Progress of CAR-NK Therapy in Cancer Treatment
Pang, Z., Wang, Z., Li, F., Feng, C., & Mu, X. N. (2022) · Cancers · doi:10.3390/cancers14174318 · Cited by 60
Burton, J., Siller‐Farfán, J. A., Pettmann, J., Salzer, B., Kutuzov, M. A., van der Merwe, P. A., & Dushek, O. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2216352120 · Cited by 63
Qi, C., Zhang, P., Liu, C., Zhang, J., Zhou, J., Yuan, J., Liu, D., Zhang, M., Gong, J., Wang, X., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.02314 · Cited by 60
Self-citationSong, M.-K., Park, B.-B., & Uhm, J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20205010 · Cited by 62
Anti-CD30 chimeric antigen receptor T cell therapy for relapsed/refractory CD30+ lymphoma patients
Wang, D., Zeng, C., Xu, B., Xu, J., Wang, J., Jiang, L., Wang, Q., Li, C., Wang, N., Huang, L., et al. (2020) · Blood Cancer Journal · doi:10.1038/s41408-020-0274-9 · Cited by 60
Transposon-Based CAR T Cells in Acute Leukemias: Where Are We Going?
Magnani, C. F., Tettamanti, S., Alberti, G., Pisani, I., Biondi, A., Serafini, M., & Gaipa, G. (2020) · Cells · doi:10.3390/cells9061337 · Cited by 64
Tasian, S. K. (2018) · Therapeutic Advances in Hematology · doi:10.1177/2040620718774268 · Cited by 60
CAR T-Cell Therapy in Hematologic Malignancies: Clinical Role, Toxicity, and Unanswered Questions
Gill, S. I., & Brudno, J. N. (2021) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_320085 · Cited by 63
Du, L., Nai, Y., Shen, M., Li, T., Huang, J., Han, X., Wang, W., Pang, D., & Jin, A. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.675179 · Cited by 59
Costa, A., Thirant, C., Kramdi, A., Pierre‐Eugène, C., Louis‐Brennetot, C., Blanchard, O., Surdez, D., Gruel, N., Lapouble, E., Pierron, G., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004807 · Cited by 60
Toward the potential cure of leukemias in the next decade
Kantarjian, H. M., Keating, M. J., & Freireich, E. J. (2018) · Cancer · doi:10.1002/cncr.31669 · Cited by 60
Zhu, J., Yin, T., Xu, Y., & Lu, X. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.28048 · Cited by 59
A dual-modal PET/near infrared fluorescent nanotag for long-term immune cell tracking
Harmsen, S., Medine, E. İ., Moroz, M. A., Nurili, F., Lobo, J. M., Dong, Y., Turkekul, M., Pillarsetty, N., Ting, R., Ponomarev, V., et al. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120630 · Cited by 58
Delivery Techniques for Enhancing CAR T Cell Therapy against Solid Tumors
Fu, R., Li, H., Li, R., McGrath, K. V., Dotti, G., & Gu, Z. (2021) · Advanced Functional Materials · doi:10.1002/adfm.202009489 · Cited by 58
Ho, J., Wang, L., Liu, Y., Ba, M., Yang, J., Zhang, X., Chen, D., Lu, P., & Li, J. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2021.03.007 · Cited by 61
Harnessing Antitumor CD4+ T Cells for Cancer Immunotherapy
Khelil, M. B., Godet, Y., Abdeljaoued, S., Borg, C., Adotévi, O., & Loyon, R. (2022) · Cancers · doi:10.3390/cancers14010260 · Cited by 63
Modulating tumor physical microenvironment for fueling CAR-T cell therapy
Luo, Z. Y., Yao, X., Li, M., Fang, D., Fei, Y., Cheng, Z., Xu, Y., & Zhu, B. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114301 · Cited by 59
No free rides: management of toxicities of novel immunotherapies in ALL, including financial
Jain, T., & Litzow, M. R. (2018) · Blood Advances · doi:10.1182/bloodadvances.2018020198 · Cited by 58
Wilson, T. L., Kim, H., Chou, C., Langfitt, D. M., Mettelman, R. C., Minervina, A. A., Allen, E. K., Métais, J., Pogorelyy, M. V., Riberdy, J. M., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1508 · Cited by 58
Implications of High Tumor Burden on Chimeric Antigen Receptor T-Cell Immunotherapy
Ventin, M., Cattaneo, G., Maggs, L., Arya, S., Wang, X., & Ferrone, C. R. (2023) · JAMA Oncology · doi:10.1001/jamaoncol.2023.4504 · Cited by 64
Self-citationHuang, Y., Shao, M., Teng, X., Si, X., Wu, L., Jiang, P., Liu, L., Cai, B., Wang, X., Han, Y., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101400 · Cited by 63
Self-citationSOCS1 is a critical checkpoint in immune homeostasis, inflammation and tumor immunity
Bidgood, G. M., Keating, N., Doggett, K., & Nicholson, S. E. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1419951 · Cited by 61
Hematopoietic Stem Cell Transplantation in Pediatric Acute Lymphoblastic Leukemia
Merli, P., Algeri, M., Bufalo, F. D., & Locatelli, F. (2019) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-019-00502-2 · Cited by 62
Zhang, X., Yang, J., Li, J., Li, W., Song, D., Lu, X., Wu, F., Li, J., Chen, D., Li, X., et al. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-03009-z · Cited by 58
Liu, D., Xu, X., Dai, Y., Zhao, X., Bao, S., Ma, W., Zha, L., Liu, S., Liu, Y., Zheng, J., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001466 · Cited by 58
Strategies to overcome tumour relapse caused by antigen escape after CAR T therapy
Lu, Y., & Fu, Z. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02334-6 · Cited by 58
Zhang, L., Song, Y., & Liu, D. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0593-5 · Cited by 59
Development of adaptive immune effector therapies in solid tumors
Comoli, P., Chabannon, C., Koehl, U., Lanza, F., Urbano-Ispizúa, Á., Hudecek, M., Ruggeri, A., Secondino, S., Bonini, C., & Pedrazzoli, P. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz285 · Cited by 57
Super-Treg: Toward a New Era of Adoptive Treg Therapy Enabled by Genetic Modifications
Amini, L., Greig, J., Schmueck‐Henneresse, M., Volk, H., Bézie, S., Reinke, P., Guillonneau, C., Wagner, D. L., & Anegón, I. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.611638 · Cited by 58
Strategies for Dodging the Obstacles in CAR T Cell Therapy
Kozani, P. S., Kozani, P. S., Rahbarizadeh, F., & Nikkhoi, S. K. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.627549 · Cited by 57
Ernst, M., Oeser, A., Besiroglu, B., Caro-Valenzuela, J., Aziz, M. A. A. E., Monsef, I., Borchmann, P., Estcourt, L. J., Skoetz, N., & Goldkuhle, M. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013365.pub2 · Cited by 57
Chimeric antigen receptor T‐cell therapies: Optimising the dose
Dasyam, N., George, P., & Weinkove, R. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14281 · Cited by 58
Lymphoblastic Lymphoma: a Concise Review
Intermesoli, T., Weber, A., Leoncin, M., Frison, L., Skert, C., & Bassan, R. (2022) · Current Oncology Reports · doi:10.1007/s11912-021-01168-x · Cited by 56
CXCL9-modified CAR T cells improve immune cell infiltration and antitumor efficacy
Tian, Y., Wen, C., Zhang, Z., Liu, Y., Li, F., Zhao, Q., Yao, C., Ni, K., Yang, S., & Zhang, Y. (2022) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-022-03193-6 · Cited by 56
Elsallab, M., Ellithi, M., Hempel, S., Abdel‐Azim, H., & Abou‐El‐Enein, M. (2023) · Cancer Gene Therapy · doi:10.1038/s41417-023-00593-3 · Cited by 56
Lu, L., Xiao, S.-X., Lin, Z., Bai, J. J., Li, W., Song, Z., Zhou, Y., Lu, B., & Wu, W. (2023) · Cell Biology and Toxicology · doi:10.1007/s10565-023-09821-w · Cited by 56
Oxidized mRNA Lipid Nanoparticles for In Situ Chimeric Antigen Receptor Monocyte Engineering
Mukalel, A. J., Hamilton, A. G., Billingsley, M. M., Li, J. J., Thatte, A. S., Han, X., Safford, H. C., Padilla, M. S., Papp, T. E., Parhiz, H., et al. (2024) · Advanced Functional Materials · doi:10.1002/adfm.202312038 · Cited by 57
Wang, J., Mou, N., Yang, Z., Li, Q., Jiang, Y., Meng, J., Liu, X., & Deng, Q. (2020) · British Journal of Haematology · doi:10.1111/bjh.16623 · Cited by 57
First immunotherapeutic CAR-T cells against the immune checkpoint protein HLA-G
Anna, F., Bôle‐Richard, E., LeMaoult, J., Escande, M. C., Lecomte, M., Certoux, J.-M., Souque, P., Garnache‐Ottou, F., Adotévi, O., Langlade‐Demoyen, P., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001998 · Cited by 56
Gutiérrez, C., Brown, A. R., Herr, M. M., Kadri, S. S., Hill, B. T., Rajendram, P., Duggal, A., Turtle, C. J., Patel, K. B., Lin, Y., et al. (2020) · Journal of Critical Care · doi:10.1016/j.jcrc.2020.04.008 · Cited by 55
Self-citationArias, J., Yu, J., Varshney, M., Inzunza, J., & Nalvarte, I. (2021) · Stem Cells Translational Medicine · doi:10.1002/sctm.20-0459 · Cited by 56
Frey, N. V. (2022) · Blood · doi:10.1182/blood.2021014892 · Cited by 57
Recent updates on allogeneic CAR-T cells in hematological malignancies
Mansoori, S., Noei, A., Maali, A., Seyed-Motahari, S. S., & Sharifzadeh, Z. (2024) · Cancer Cell International · doi:10.1186/s12935-024-03479-y · Cited by 57
SynNotch CAR-T cell, when synthetic biology and immunology meet again
Shirzadian, M., Moori, S., Rabbani, R., & Rahbarizadeh, F. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1545270 · Cited by 55
Rataj, F., Jacobi, S. J., Stoiber, S., Asang, F., Ogonek, J., Tokarew, N. J. A., Cadilha, B. L., van Puijenbroek, E., Heise, C., Duewell, P., et al. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0341-1 · Cited by 55
Lapteva, N., Gilbert, M. H., Diaconu, I., Rollins, L. A., Al-Sabbagh, M., Naik, S., Krance, R. A., Tripic, T., Hiregange, M., Raghavan, D., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3199 · Cited by 56
Telomerase-based Cancer Therapeutics: A Review on their Clinical Trials
Relitti, N., Saraswati, A. P., Federico, S., Khan, T., Brindisi, M., Zisterer, D. M., Brogi, S., Gemma, S., Butini, S., & Campiani, G. (2020) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026620666200102104930 · Cited by 55
Management of toxicities associated with novel immunotherapy agents in acute lymphoblastic leukemia
Jain, T., & Litzow, M. R. (2020) · Therapeutic Advances in Hematology · doi:10.1177/2040620719899897 · Cited by 55
Xue, L., Yi, Y., Xu, Q., Wang, L., Yang, X., Zhang, Y., Hua, X., Chai, X., Yang, J., Chen, Y., et al. (2021) · Cell Discovery · doi:10.1038/s41421-021-00299-6 · Cited by 57
Self-citation
Metadata
- Authors
- Park, J. H., Rivière, I., Gonen, M., Wang, X., Sénéchal, B., Curran, K. J., Sauter, C., Wang, Y., Santomasso, B., Mead, E., Roshal, M., Maslak, P., Davila, M., Brentjens, R. J., & Sadelain, M.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- From the Leukemia Service, Department of Medicine (J.H.P., C.S., P.M., R.J.B.), the Michael G. Harris Cell Therapy and Cell Engineering Facility (I.R., X.W., B. Sénéchal, Y.W.), the Center for Cell Engineering (J.H.P., I.R., X.W., R.J.B., M.S.), and the Departments of Epidemiology and Biostatistics (M.G.), Pediatrics (K.J.C.), Neurology (B. Santomasso), Anesthesiology and Critical Care Medicine (E.M.), and Pathology (M.R.), Memorial Sloan Kettering Cancer Center, and the Department of Medicine, Joan...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-02
- Volume
- 378
- Issue
- 5
- Pages
- 449-459
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC6637939
- OpenAlex
- W2787621143
- Cited by
- 2,688
- References
- 24
- Citations by year
- 2026: 164 · 2025: 235 · 2024: 306 · 2023: 351 · 2022: 365 · 2021: 403 · 2020: 412 · 2019: 290 · 2018: 156
- FWCI
- 118.36
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Comprehensive Cancer Network Foundation (Young Investigator Award)
- Emerald Foundation
- National Institute of Health (R01CA138738-05, P01CA059350, P01CA190174-01)
- Leukemia and Lymphoma Society (Career Development Award)
- American Society of Clinical Oncology (Career Development Award)
- Memorial Sloan Kettering Cancer Center Support Grant (P30CA008748)
- Juno Therapeutics
- Center for Experimental Therapeutics at Memorial Sloan Kettering Cancer Center
- Stand Up To Cancer
- William Lawrence and Blanche Hughes Foundation
- Annual Terry Fox Run for Cancer Research
- Carson Family Charitable Trust
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Health Sciences › Medicine › Hematology › Acute Lymphoblastic Leukemia research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- CD19 CAR T cells, B-cell acute lymphoblastic leukemia, relapsed leukemia, autologous T cell therapy, cytokine release syndrome, neurotoxicity, disease burden, bone marrow blasts, event-free survival, overall survival, long-term outcomes
- MeSH terms
- Adult, Aged, Follow-Up Studies, Humans, Middle Aged, Receptors, Antigen, T-Cell, Recurrence, Remission Induction, T-Lymphocytes, Survival Analysis, Cytokines, Precursor Cell Lymphoblastic Leukemia-Lymphoma
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
